← Leaderboards
Ross Okimoto
University Of California, San Francisco
$3,105,765
Attributed
$3,402,279
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $962.5K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,402,279 · 3
By mechanism
R37$1,922,391 · 1
K08$886,860 · 1
R01$593,028 · 1
Top collaborators
- Hua E Yu1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Trever G Bivona$22,714,857
- Elizabeth Erin Crouch$2,484,315
- Elizabeth E Hwang$179,528
- Eugene Ozhinsky$603,439
- Cuyler Luck$92,382
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingMolecularMalignant NeoplasmsGenetic TranscriptionSignal TransductionGeneticRegulationProtein DegradationTumorPatient-Focused OutcomesPathway InteractionsImproved OutcomeExperimental StudyNeoplasm MetastasisBindingInnovationOncogenicProtein ExpressionCessation Of LifeLaboratoriesEtv4 GenePre-ClinicalHyperactivityInsight
Grant awards (12)
The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression$593,028
R01 · FY2025 · CA
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas$369,431
R37 · FY2025 · CA · contact PI
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas$369,431
R37 · FY2024 · CA · contact PI
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas$369,431
R37 · FY2023 · CA · contact PI
Negative MAPK-RAS-ERK pathway regulation to sustain CIC-DUX4 expression$75,236
R37 · FY2023 · CA · contact PI
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas$369,431
R37 · FY2022 · CA · contact PI
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis$177,372
K08 · FY2022 · CA · contact PI
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas$369,431
R37 · FY2021 · CA · contact PI
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis$177,372
K08 · FY2021 · CA · contact PI
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis$177,372
K08 · FY2020 · CA · contact PI
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis$177,372
K08 · FY2019 · CA · contact PI
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis$177,372
K08 · FY2018 · CA · contact PI